Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised three week double-blind crossover study to compare the efficacy and safety of CNV2197944 75 mg tid versus placebo in the treatment of neuropathic pain in patients with diabetic peripheral neuropathy.

Next Previous
X
Search
Trial Profile

A randomised three week double-blind crossover study to compare the efficacy and safety of CNV2197944 75 mg tid versus placebo in the treatment of neuropathic pain in patients with diabetic peripheral neuropathy.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2014

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CNV 2197944 (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain; Peripheral neuropathies
  • Focus Therapeutic Use
  • Sponsors Convergence Pharmaceuticals

    • Most Recent Events

    • 27 Sep 2014 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 28 Jan 2014 Planned End Date changed from 1 Sep 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov record.
    • 08 Jul 2013 Status changed to recruiting according to a Convergence Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top